Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaRegenerative Medicine ...

John Sacaria Thirusailam, once very active in life, was forced to leave his well-paid job at the age of 44 after being ...

The Erling-Persson Foundation is donating SEK 8 million to KI researcher Johan Ericson to fund the verification of his ATMP ...

A new study reveals that entacapone, a drug used to treat Parkinson’s disease, significantly disrupts the gut microbiome by ...

Cambridge researchers are developing implants to help repair brain pathways damaged by Parkinson’s disease. As part of a £69 ...

| Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a ...

At the Rutgers American Parkinson Disease Association Center for Advanced Research —one of only nine such centers—we don’t just seek to treat the symptoms of Parkinson’s but to cure it. By focusing on ...

Genome-wide association studies (GWASs) have linked genetic variants to neuropsychiatric disorders, but their regulatory roles in non-coding regions remain largely unclear. Using the LUHMES neuronal ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

Eight patients with advanced Parkinson’s disease were included in the study, and all underwent DBS implantation in the subthalamic nucleus. Clinical assessments were made by both unblinded ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...